Clinical Trial Update: PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial update for belinostat (PXD101) as second-line therapy in unresectable malignant mesothelioma; study completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelioid Mesothelioma
• Malignant Mesothelioma
• Sarcomatoid Mesothelioma

Drugs mentioned

• BELEODAQ (BELINOSTAT)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2014-12-29